Neoplasm

Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Retrieved on: 
星期四, 四月 18, 2024
Eurostat, Diagnosis, Civil service commission, Optic nerve, Brain, Enzyme, Growth, Cell, NF1, Disease, Nervous system, Risk, Groin, Patient, Committee, Knowledge, Neoplasm, Regulation, Cancer, EMA, IRIS, Eye, European, Therapy, COMP, Safety, European Commission, Marketing, Medicine, Pharmaceutical industry

Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Key Points: 


Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Retrieved on: 
星期四, 四月 18, 2024
Eurostat, Diagnosis, Civil service commission, X-ray, Growth, Medicine, Disease, Patient, Ageing, Committee, Knowledge, Tissue, Neoplasm, Light, Cutaneous T-cell lymphoma, Regulation, Cancer, EMA, IRIS, Quality of life, Reactive oxygen species, Lymph, CTCL, Clinical trial, European, Skin, COMP, Oxygen, European Commission, Immune system, Safety, Carmustine, Alfa, Marketing, Lymphatic system, Pharmaceutical industry

Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

Key Points: 


Orphan designation: Synthetic hypericin Treatment of cutaneous T-cell lymphoma, 28/07/2015 Positive

EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Retrieved on: 
星期三, 四月 10, 2024
Certification, Radiation, Prostate cancer, Prostate, Seed, Eye, MDR, Neoplasm, Way, Brachytherapy, Medical device regulation, Health, Medical device

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Key Points: 
  • Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
    The issuer is solely responsible for the content of this announcement.
  • This important milestone guarantees a high level of patient safety and the long-term availability of the seeds within the EU.
  • Prostate seeds have been manufactured and internationally marketed by Eckert & Ziegler since 1999 and contribute several million euros in annual sales to the Eckert & Ziegler Group's earnings.
  • This is not only a significant achievement for the distribution of our brachytherapy products, but for the entire Eckert & Ziegler Group," explained Katrin Antonenko, Managing Director of Eckert & Ziegler BEBIG GmbH.

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Retrieved on: 
星期三, 四月 10, 2024
Malignancy, Spanish mythology, State university system, Patient, Sale, Renal cell carcinoma, Clinical trial, Neoplasm, Therapy, Depreciation, HPHA, USD, Marketing, GLP, Health, Research, ATACS, EPO, Immune system, ADC, BLA, ATAC, Food, Biologics license application, Disease, Magenta, Multiple myeloma, AACR, GCC, Annual report, FDA, Diagnosis, EUR, Supervisory board, Accounting, PET, EDT, Spacecraft, Amanitin, European Patent Convention, Patent, Eli Lilly and Company, Binghamton University, Pharmaceutical industry

Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).

Key Points: 
  • Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).
  • As a result, Heidelberg Pharma lost sales revenue in the low single-digit millions for the 2023 financial year.
  • In April 2023, Heidelberg Pharma signed a termination agreement with Magenta under which all licensed ATAC rights and some Magenta patents were assumed by Heidelberg Pharma.
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE

Retrieved on: 
星期三, 四月 10, 2024
Antigen presentation, Neoplasm, Microsoft Exchange Server, DTC, Therapy, Vaccination, Melanoma, OTCQB, Antigen, Vaccine

When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.

Key Points: 
  • When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.
  • Compared to current anti-cancer strategies, vaccination can stimulate specific immune responses capable of potentially curing established tumors.
  • In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses.
  • Although the ARMTM vaccine can effectively present antigens to responding T cells, the large amount of antigen preparation required to generate the cellular vaccine might represent challenges in the clinic.

PDT (PDT) Is Now Available for Trading on LBank Exchange

Retrieved on: 
星期五, 三月 29, 2024
Blood, Blockchain, Cancer, Investment, Neoplasm, Decentralized finance, Oxygen, Ecosystem, Cryptocurrency

PDT (PDT) on the SNOWSEED platform introduces a Web3 economy that integrates blockchain into healthcare to foster a broad ecosystem where $PDT serves as a key medium of value exchange, enhancing user involvement and experiences across various industries.

Key Points: 
  • PDT (PDT) on the SNOWSEED platform introduces a Web3 economy that integrates blockchain into healthcare to foster a broad ecosystem where $PDT serves as a key medium of value exchange, enhancing user involvement and experiences across various industries.
  • LBank Exchange is thrilled to announce the upcoming listing of PDT (PDT), an innovative and advanced treatment modality for cancer, leveraging the power of light-sensitive drugs known as photosensitizers, along with light exposure, to destroy cancer cells.
  • The Snowseed Platform, through the WiseAlya Project, aims to revolutionize the way PDT is utilized and commercialized, particularly in Indonesia.
  • This development is a key component of the WiseAlya Project's strategy to introduce more effective and patient-friendly PDT treatments in Indonesia.

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期二, 四月 9, 2024
Patient, ICB, Neoplasm, Cancer, Ubiquitin, Biology, AACR, Phenotype, Aberrant, MAVS, Autoimmune disease, PD-1, Pharmaceutical industry

AUSTIN, TX and DURHAM, NC, April 09, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data demonstrating the therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy. These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.

Key Points: 
  • These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
  • Our efforts in helping to define the underlying biology of acquired resistance were recently revealed with a publication in Cancer Cell,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • TRIM7 also contributes to PD-1 acquired resistance through ubiquitination and degradation of STING and MAVS.
  • A copy of the AACR presentation will be available on the Investors section of the Company’s website shortly after the event.

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

Retrieved on: 
星期二, 四月 9, 2024
Lung cancer, Survival, NSCLC, Immunotherapy, Colorectal cancer, Central nervous system, Patient, CNS, Neoplasm, AACR, PDX, Clinical trial, Pancreatic cancer, Cancer, CRC, Metastasis, Proteome, PD-1, Pharmaceutical industry

- The Phase 1/2 PROSPER clinical trial is currently evaluating FMC-376 in patients with KRASG12C cancers, regardless of prior KRAS inhibitor therapy BOSTON and SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today presented new preclinical data on its KRASG12C inhibitor, FMC-376, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. The new findings demonstrate FMC-376’s potential to overcome known mechanisms of innate and acquired resistance and in a CNS model of metastasis as a monotherapy and increase the efficacy of PD-1 immunotherapy in combination.

Key Points: 
  • “These data demonstrate FMC-376’s unmatched potential to overcome over 90 percent of known resistance mechanisms, including those cancers that have become refractory to approved KRAS inhibitors.
  • The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the resistance and lack of response seen with current KRASG12C single-acting treatments.
  • These results reinforce that FMC-376 has the potential to overcome limitations of single-acting KRASG12C inhibitors.
  • The combination of FMC-376 with an immune checkpoint inhibitor also leads to an increased response and survival in preclinical models.

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
星期二, 四月 9, 2024
TME, Development, Biotechnology, Cell, Teff, SAN, Tumor microenvironment, Cancer, AACR, Neoplasm, Wigginton, Huangshan, Autoimmune disease, PD-1, Vaccine

Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, by creating an IL-18 binding protein-resistant molecule and integrating it with PD-1 checkpoint blockade to create BPT567, a first-in-class PD1-IL18 immunoconjugate.

Key Points: 
  • Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, by creating an IL-18 binding protein-resistant molecule and integrating it with PD-1 checkpoint blockade to create BPT567, a first-in-class PD1-IL18 immunoconjugate.
  • Antibody-cytokine conjugates leverage orthogonal mechanisms of action (MoA) in one molecule to induce potent antitumor immune responses.
  • “BPT567 is designed to coordinately engage antigen-experienced Teff cells that are known to co-express both PD-1 and the IL-18 receptor.
  • It is anticipated that this profile could ultimately contribute to an improved risk-benefit profile for BPT567 in the clinical setting”.

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
星期二, 四月 9, 2024
TME, Toxicity, Metastasis, Enzyme, Survival, Cleavage, IL-2R, Brain, Patient, Tumor microenvironment, Mouse, Breast, Cancer, Prostate, Science, MDNA, AACR, TSX, Neoplasm, Metalloproteinase, Breast cancer, Poster, Medical imaging

TORONTO and HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data on MDNA113, the Company’s novel T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, an IL-13R⍺2 (Interleukin-13 receptor alpha2) specific superkine featuring unique masking and tumor targeting characteristics, were presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9th, 2024.

Key Points: 
  • Key findings presented at the conference include:
    When not activated, MDNA113 shows reduced IL-2R agonism with no change to PD-1/PDL-1 blockade activity.
  • MDNA113 selectively binds IL-13R⍺2 positive tumor cells in vitro, and durably accumulates (>7 days) in IL-13R⍺2 positive tumors in mice.
  • Single neoadjuvant treatment with MDNA113 in a highly invasive orthotopic 4T1.2 breast cancer model significantly increases survival by preventing metastasis.
  • It will be also available on the Scientific Presentations page of Medicenna’s website following the conclusion of the 2024 Annual Meeting of AACR.